Novel compound, organic cation transporter 3 detection agent and organic cation transporter 3 activity inhibitor, WO2015002150 A1: a patent evaluation

References

• Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–236.
   PubMed Web of Science ®Google Scholar
• Wright SH. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol. 2005;204:309–319.
   PubMed Web of Science ®Google Scholar
• Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260–1287.
   PubMed Web of Science ®Google Scholar
• Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 2013;34:413–435.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227–1251.
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, et al. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 2011;201:105–167.
   PubMedGoogle Scholar
• Koepsell H. Role of organic cation transporters in drug-drug interaction. Expert Opin Drug Metab Toxicol. 2015;11:1619–1633.
   PubMed Web of Science ®Google Scholar
• Courousse T, Gautron S. Role of organic cation transporters (OCTs) in the brain. Pharmacol Ther. 2015;146:94–103.
   PubMed Web of Science ®Google Scholar
• Wu X, Kekuda R, Huang W, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998;273:32776–32786.
   PubMed Web of Science ®Google Scholar
• Daws LC, Koek W, Mitchell NC. Revisiting serotonin reuptake inhibitors and the therapeutic potential of ‘uptake-2’ in psychiatric disorders. ACS Chem Neurosci. 2013;4:16–21.
   PubMed Web of Science ®Google Scholar
• Duan H, Wang J. Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010;335:743–753.
   PubMed Web of Science ®Google Scholar
• Mooney JJ, Samson JA, Hennen J, et al. Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3). J Psychiatr Res. 2008;42:605–611.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Wu P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015;63:1002–1009.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Appel DI, Grundemann D, et al. Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res. 2012;65:491–496.
   PubMed Web of Science ®Google Scholar
• Nobuyuki Suzuki HY. Novel compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor. WO 2015002150 A1. 2015.
   Google Scholar
• Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005;315:1288–1297.
   PubMed Web of Science ®Google Scholar
• Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002;136:829–836.
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Taniguchi T, Fujiwara M, et al. Alterations in alpha adrenergic receptors in human cerebral arteries after subarachnoid hemorrhage. Stroke. 1985;16:53–58.
   PubMed Web of Science ®Google Scholar
• Engel K, Wang J. Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol. 2005;68:1397–1407.
   PubMed Web of Science ®Google Scholar
• Duan H, Hu T, Foti RS, et al. Potent and selective inhibition of plasma membrane monoamine transporter by HIV protease inhibitors. Drug Metab Dispos. 2015;43:1773–1780.
   PubMedGoogle Scholar
• Pelis RM, Wright SH. SLC22, SLC44, and SLC47 transporters–organic anion and cation transporters: molecular and cellular properties. Curr Top Membr. 2014;73:233–261.
   PubMed Web of Science ®Google Scholar
• Motohashi H, Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013;15:581–588.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Hanaoka H, Liang JX, et al. PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine. J Nucl Med. 2010;51:1472–1479.
   PubMed Web of Science ®Google Scholar
• Zhang H, Huang R, Pillarsetty N, et al. Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging. 2014;41:322–332.
   PubMed Web of Science ®Google Scholar
• Zhang H, Huang R, Cheung NK, et al. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014;20:2182–2191.
   PubMed Web of Science ®Google Scholar
• Steru L, Chermat R, Thierry B, et al. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85:367–370.
   PubMed Web of Science ®Google Scholar
• Can A, Dao DT, Arad M, et al. The mouse forced swim test. J Vis Exp. 2012;59:e3638.
   PubMed Web of Science ®Google Scholar
• Massmann V, Edemir B, Schlatter E, et al. The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch. 2014;466:517–527.
   PubMed Web of Science ®Google Scholar